Prostate cancer patients with higher Gleason scores (≥8) have substantially lower SFMBT2 expression than patients with lower Gleason scores, indicating that SFMBT2 may have an anti-metastatic function [26]. The gene discussed is SFMBT2; the disease is Familial prostate cancer.